Needham & Company Reiterates a 'Buy' on Hologic (HOLX); Waiting 'Til November for GPRO Insight

July 31, 2012 8:07 AM EDT Send to a Friend
Get Alerts HOLX Hot Sheet
Price: $21.09 +1.05%

Rating Summary:
    16 Buy, 6 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 35 | New: 23
Trade HOLX Now!
Needham & Company reiterates a 'Buy' on Hologic (NASDAQ: HOLX) price target of $22.00.

Analyst, Dalton Chandler, said, "We think investors were hoping to get some insight into the financial outlook for the combined HOLX and Gen-Probe (Nasdaq: GPRO), but apparently they will have to wait until November for that. Our “best guess”, “back of the envelope” estimate is about $2.8 B in revenue and $1.75 in pro forma EPS, which would mean the shares currently trade for a P/E a shade over 10x. That would put the shares at about a 33% discount to the peer group. While HOLX’s debt load suggests some discount is appropriate, we think this is excessive."

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $18.26 yesterday, with a 52 week range of $13.90-$22.16.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, Mergers and Acquisitions

Related Entities

Needham & Company

Add Your Comment